Sage Inks Licensing Deal with Causaly’s AI Platform Focusing on Drug Discovery Research

In a new publishing deal, Causaly and Sage have announced a partnership to bring full-text scientific peer-reviewed literature into the world of AI-powered drug discovery research. The deal also marks Causaly’s first partnership with a major STM publisher.

The post Sage Inks Licensing Deal with Causaly’s AI Platform Focusing on Drug Discovery Research appeared first on GEN - Genetic Engineering and Biotechnology News.